Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12N-005/00
C12N-005/077
출원번호
US-0471916
(2006-06-20)
등록번호
US-9062289
(2015-06-23)
발명자
/ 주소
Gold, Joseph D.
Hassanipour, Mohammad
출원인 / 주소
Asterias Biotherapeutics, Inc.
대리인 / 주소
Kauppinen, Krista P.
인용정보
피인용 횟수 :
0인용 특허 :
18
초록▼
The present application describes the new methods for the differentiation of primate pluripotent stem cells into cardiomyocyte-lineage cells. The methods utilize sequential culturing of the primate pluripotent stem cells in certain growth factors to produce cardiomyocyte-lineage cells. In certain em
The present application describes the new methods for the differentiation of primate pluripotent stem cells into cardiomyocyte-lineage cells. The methods utilize sequential culturing of the primate pluripotent stem cells in certain growth factors to produce cardiomyocyte-lineage cells. In certain embodiments of the invention, the population of cells produced by the sequential culturing is further enriched for cardiomyocyte-lineage cells so as to produce a higher percentage of those cells.
대표청구항▼
1. A method for obtaining a population of cells comprising α myosin heavy chain (αMHC) expressing cells from human embryonic stem (hES) cells by direct differentiation, comprising a) culturing the hES cells in the presence of Activin A in the absence of a BMP; b) subsequently culturing the cells in
1. A method for obtaining a population of cells comprising α myosin heavy chain (αMHC) expressing cells from human embryonic stem (hES) cells by direct differentiation, comprising a) culturing the hES cells in the presence of Activin A in the absence of a BMP; b) subsequently culturing the cells in the presence of a BMP and in the absence of Activin A for between three and five days, wherein the BMP is selected from the group consisting of BMP-2 and BMP-4 and c) subsequently culturing the cells in the presence of an insulin like growth factor (IGF) in the absence of Activin A or a BMP, wherein the IGF is selected from the group consisting of IGF-I and IGF-II, thereby producing a cell population comprising α myosin heavy chain (αMHC) expressing cells. 2. The method of claim 1, wherein the BMP of step b) is BMP-4. 3. The method of claim 1, wherein the hES cells are cultured in the presence of Activin A for about one day and then subsequently cultured in the presence of the BMP for about four days. 4. The method of claim 1, wherein the culturing of step c) is performed for at least one week. 5. The method of claim 1, wherein the culturing of step c) is performed for at least two weeks. 6. The method of claim 1, wherein the IGF of step c) is IGF-I. 7. The method of claim 1, wherein the method does not comprise a step in which embryoid bodies are formed. 8. The method of claim 1, wherein the method further comprises harvesting cells from the culture subsequent to the IGF culturing step and enriching the harvested cell population for α myosin heavy chain (αMHC) expressing cells. 9. The method of claim 8, wherein the harvested cell population is enriched by a density gradient. 10. The method of claim 8, wherein the enriching the harvested cell population of α myosin heavy chain (αMHC) expressing cells comprises the formation of clusters of cells. 11. A method for obtaining an enriched population of α myosin heavy chain (αMHC) expressing cells from hES cells by direct differentiation, comprising a) culturing the hES cells in a serum-free medium in the presence of Activin A in the absence of a BMP for about one day; b) subsequently culturing in a serum-free medium in the presence of BMP-4 in the absence of Activin A for about four days; c) subsequently culturing in a serum-free medium in the presence of IGF-I for about five days or more; d) harvesting cells from the culture and e) enriching the harvested cell population for α myosin heavy chain (αMHC) expressing cells, thereby producing an enriched population of α myosin heavy chain (αMHC) expressing cells. 12. A method for obtaining a population of cells comprising α myosin heavy chain (αMHC) expressing cells from cells expressing stage specific embryonic antigen 3 (SSEA3), stage specific embryonic antigen 4 (SSEA4) and markers Tra-1-60 and Tra-1-81 by direct differentiation, comprising a) culturing the cells expressing stage specific embryonic antigen 3 (SSEA3), state stage specific embryonic antigen 4 (SSEA4) and markers Tra-1-60 and Tra-1-81 in the presence of Activin A in the absence of a BMP; b) subsequently culturing the cells in the presence of BMP-2 or BMP-4 and the absence of Activin A for between three and five days; and c) subsequently culturing the cells in the presence of an IGF in the absence of Activin A or a BMP wherein the IGF is selected from the group consisting of IGF-I and IGF-II, thereby producing a cell population comprising α myosin heavy chain (αMHC) expressing cells. 13. The method of claim 12, wherein the BMP of step b) is BMP-4. 14. The method of claim 12, wherein the cells expressing stage specific antigen embryonic antigen 3 (SSEA3), stage specific antigen embryonic antigen 4 (SSEA4) and markers Tra-1-60 and Tra-1-81 are cultured in the presence of Activin A for about one day and then subsequently cultured in the presence of the BMP for about four days. 15. The method of claim 12, wherein the culturing in the presence of an IGF is performed for at least one week. 16. The method of claim 12, wherein the culturing in the presence of an IGF is performed for at least two weeks. 17. The method of claim 12, wherein the IGF is IGF-I. 18. The method of claim 1, wherein the α myosin heavy chain (αMHC) expressing cells express cardiac troponin I. 19. The method of claim 11, wherein the α myosin heavy chain (αMHC) expressing cells express cardiac troponin I. 20. The method of claim 12, wherein the α myosin heavy chain (αMHC) expressing cells express cardiac troponin I. 21. The method of claim 1, wherein the α myosin heavy chain (αMHC) expressing cells beat in culture. 22. The method of claim 11, wherein the α myosin heavy chain (αMHC) expressing cells beat in culture. 23. The method of claim 12, wherein the α myosin heavy chain (αMHC) expressing cells beat in culture.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (18)
Xiao, Yong-Fu; Morgan, James P., Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated.
Gold,Joseph D.; Hassanipour,Mohammad; Collins,Lila R.; Xu,Chunhui, Direct differentiation method for making cardiomyocytes from human embryonic stem cells.
Smith David A. (3244 Belle Ct. Royal Oak MI 48073) Townsend Laurace E. (868 Whittier Grosse Pointe Park MI 48230), Method of isolation, culture and proliferation of human atrial myocytes.
Mickle Donald A. G.,CAXITX M5M 2X9 ; Li Ren-Ke,CAXITX M1V 1B4 ; Weisel Richard D.,CAXITX M4X 1S8, Transplants for myocardial scars and methods and cellular preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.